Clinical Trials Browser

Phase 3 × Tumor Lysis Syndrome × obinutuzumab × Clear all

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell